Ipsen: positive final data in advanced NETs

(CercleFinance.com) - Ipsen announces the publication of positive final data for the phase III CABINET trial evaluating its Cabometyx versus placebo, corroborating its efficacy benefits in advanced neuroendocrine tumors (NET).


These data demonstrated a statistically and clinically significant reduction in the risk of disease progression or death with Cabometyx in pancreatic and extra-pancreatic NETs.

These data were presented at the ESMO 2024 meeting and published in the NEJM. Ipsen has submitted an indication extension application for marketing authorization to the European Medicines Agency.

Approved treatment options are currently limited for advanced NETs depending on initial disease location, while no treatment has been approved for lung NETs that have progressed after prior systemic therapy, Ipsen notes.


Copyright (c) 2024 CercleFinance.com. All rights reserved.